ALX Oncology Company
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Total Funding:
166000000
Headquarters:
San Francisco, California, United States
Funding Status:
IPO
Employee Number:
11-50
Estimated Revenue:
Less than $1M
Last Funding Type:
Initial Coin Offering
Technology:
Cancer
Investor Type:
IPO
Last Funding Date:
2020
Investors Number:
10
Founded Date:
2015
Industry:
Biopharma, Biotechnology, Health Care, Life Science, Therapeutics